Ameriprise Financial Inc Hutchmed (China) LTD Transaction History

Ameriprise Financial Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Ameriprise Financial Inc holds 15,358 shares of HCM stock, worth $202,879. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,358
Previous 15,521 1.05%
Holding current value
$202,879
Previous $265,000 13.21%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$16.03 - $20.31 $2,612 - $3,310
-163 Reduced 1.05%
15,358 $300,000
Q2 2024

Aug 14, 2024
SELL
$16.36 - $21.78 $25,505 - $33,955
-1,559 Reduced 9.13%
15,521 $265,000
Q1 2024

May 15, 2024
SELL
$12.08 - $18.56 $38,619 - $59,336
-3,197 Reduced 15.77%
17,080 $286,000
Q4 2023

Feb 14, 2024
SELL
$16.25 - $20.23 $5,817 - $7,242
-358 Reduced 1.73%
20,277 $367,000
Q3 2023

Nov 14, 2023
BUY
$11.85 - $16.95 $38,085 - $54,477
3,214 Added 18.45%
20,635 $349,000
Q2 2023

Aug 14, 2023
SELL
$10.78 - $17.73 $6,112 - $10,052
-567 Reduced 3.15%
17,421 $209,000
Q1 2023

May 15, 2023
BUY
$13.02 - $19.87 $1,666 - $2,543
128 Added 0.72%
17,988 $234,000
Q4 2022

Feb 14, 2023
BUY
$7.65 - $15.51 $136,629 - $277,008
17,860 New
17,860 $263,000
Q1 2022

May 16, 2022
SELL
$15.52 - $35.65 $592,041 - $1.36 Million
-38,147 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$28.89 - $35.33 $1.1 Million - $1.35 Million
38,147 New
38,147 $1.18 Million

Others Institutions Holding HCM

# of Institutions
66
Shares Held
6.76M
Call Options Held
6.2K
Put Options Held
1.1K
View Full List

About HUTCHMED (China) Ltd

HCM Quotes by TradingView
  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.28B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email